这家因信使RNA新冠疫苗而闻名的生物技术公司，正利用类似技术开发针对皮肤癌、肺癌及其他类型肿瘤的癌症疗法。在周四与分析师举行的会议上，公司高管透露了这一信息。此外，一项潜在的新型自身免疫性疾病疗法，采用了基于细胞的机制，即CAR-T技术。
莫德纳股价周五上涨超过10%。此前，该公司公布了一项针对自身免疫性疾病的新治疗计划，并概述了多项实验性药物项目，这些项目有望在未来几年帮助其业务多元化，不再局限于新冠疫苗领域。
今年以来，随着市场对该公司新药获批前景的乐观情绪升温，莫德纳股价已累计上涨超过一倍。这其中包括其与默克公司共同开发的一款实验性黑色素瘤疫苗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.